Xentry, a new class of cell-penetrating peptide uniquely equipped for delivery of drugs

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Montrose, Kristopher ^a   Yang, Yi ^a   Sun, Xueying ^a   Wiles, Siouxsie ^a   Krissansen, Geoffrey W ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PENETRATING PEPTIDE; DRUG CARRIER;

AMINO ACID SEQUENCE; ARTICLE; CHEMISTRY; EXPERIMENTAL NEOPLASM; HUMAN; METABOLIC CLEARANCE RATE; METABOLISM; MOLECULAR GENETICS; TUMOR CELL LINE;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; DRUG CARRIERS; HUMANS; METABOLIC CLEARANCE RATE; MOLECULAR SEQUENCE DATA; NEOPLASMS, EXPERIMENTAL;

EID: 84876536009     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep01661     Document Type: Article

References (31)

1. Fonseca, S. B., Pereira, M. P. & Kelley, S. O. Recent advances in the use of cellpenetrating peptides for medical and biological applications. Adv. Drug Deliv. Rev. 61, 953-964 (2009).
2. Johnson, R. M., Harrison, S. D. & Maclean, D. Therapeutic applications of cellpenetrating peptides. Methods Mol. Biol. 683, 535-551 (2011).
3. Sebbage, V. Cell-penetrating peptides and their therapeutic applications. Biosci. Horizons 2, 64-72 (2009).
4. Gautam, A. et al. CPPsite: a curated database of cell penetrating peptides. Database (Oxford) 2012, bas015 (2012).
5. Trabulo, S., Cardoso, A. L., Mano, M. & De Lima, M. C. P. Cell-penetrating peptides-Mechanisms of cellular uptake and generation of delivery systems. Pharmaceuticals 3, 961-993 (2010).
6. Green, M. & Loewenstein, P. M. Autonomous functional domains of chemically synthesized human immunodeficiency virus Tat trans-activator protein. Cell 55, 1179-1188 (1988). (Pubitemid 19020070)
7. Mitchell, D. J., Kim, D. T., Steinman, L., Fathman, C. G. & Rothbard, J. B. Polyarginine enters cells more efficiently than other polycationic homopolymers. J. Pept. Res. 56, 318-325 (2000).
8. Morris, M. C.,Vidal, P., Chaloin, L., Heitz, F.&Divita, G. Anew peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res. 25, 2730-2736 (1997). (Pubitemid 27299785)
9. Chaloin, L. et al. Design of carrier peptide-oligonucleotide conjugates with rapid membrane translocation and nuclear localization properties. Biochem. Biophys. Res. Commun. 243, 601-608 (1998). (Pubitemid 28414071)
10. Elliott, G. & O'Hare, P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 88, 223-233 (1997). (Pubitemid 28015871)
11. Murakami, S. Hepatitis B virus X-protein: Structure, function, and biology. Intervirol. 42, 81-99 (1999). (Pubitemid 29433577)
12. Kew, M. C. Hepatitis B virus x protein in the pathogenesis of hepatitis B virusinduced hepatocellular carcinoma. J. Gastroenterol. Hepatol. 26 Suppl 1, 144-152 (2011).
13. Hafner, A., Brandenburg, B. & Hildt, E. Reconstitution of gene expression from a regulatory-protein-deficient hepatitis B virus genome by cell-permeable HBx protein. EMBO Rep. 4, 767-773 (2003). (Pubitemid 37069203)
14. Palm-Apergi, C., Lönn, P. & Dowdy, S. F. Do cell-penetrating peptides actually "penetrate" cellular membranes? Mol Ther. 20, 695-697 (2012).
15. Shafti-Keramat, S. et al. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J. Virol. 77, 13125-13135 (2003). (Pubitemid 37494308)
16. Letoha, T. et al. Cell-penetrating peptide exploited syndecans. Biochim. Biophys. Acta 1798, 2258-2265 (2010).
17. Fujimoto, T., Kogo, H., Nomura, R. &Une, T. Isoforms of caveolin-1 and caveolar structure. J. Cell Sci. 113 Pt 19, 3509-3517 (2000).
18. Tap, W. D. et al. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia 12, 637-649 (2010).
19. Wyman, T. B. et al. Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers. Biochemistry 36, 3008-3017 (1997). (Pubitemid 27138586)
20. Langer, M. & Beck-Sickinger, A. G. Peptides as carrier for tumor diagnosis and treatment. Curr. Med. Chem. Anticancer Agents 1, 71-93 (2001).
21. Sanderson, R. D., Lalor, P. & Bernfield, M. Blymphocytes express and lose syndecan at specific stages of differentiation. Cell Regul. 1, 27-35 (1989).
22. Teixé, T. et al. Syndecan-2 and-4 expressed on activated primary human CD41 lymphocytes can regulate T cell activation. Mol. Immunol. 45, 2905-2919 (2008).
23. Poon, G. M. & Gariépy, J. Cell-surface proteoglycans as molecular portals for cationic peptide and polymer entry into cells. Biochem. Soc. Trans. 35, 788-793 (2007). (Pubitemid 47310369)
24. Lambaerts, K.,Wilcox-Adelman, S. A. & Pascale Zimmermann, P. The signalling mechanisms of syndecan heparan sulphate proteoglycans. Curr. Opin. Cell Biol. 21, 662-669 (2009).
25. Ohkawara, B., Glinka, A. & Niehrs, C. Rspo3 binds syndecan 4 and induces Wnt/PCP signaling via clathrin-mediated endocytosis to promote morphogenesis. Dev. Cell 20, 303-314 (2011).
26. Johri, M. K., Mishra, R., Chhatbar, C., Unni, S. K. & Singh, S. K. Tits and bits of HIV Tat protein. Expert Opin. Biol. Ther. 11, 269-283 (2011).
27. Campbell, G. R. et al. The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis. J. Biol. Chem. 279, 48197-48204 (2004). (Pubitemid 39540975)
28. Laakkonen, P. & Vuorinen, K. Homing peptides as targeted delivery vehicles. Integr. Biol. 2, 326-337 (2010).
29. Shadidi, M.&Sioud, M. Selective targeting of cancer cells using synthetic peptides. Drug Resist. Updates 6, 363-371 (2003). (Pubitemid 38173587)
30. Jiang, T.,Olson, E. S., Nguyen, Q. T., Roy, M., Jennings, P. A.&Tsien, R. Y. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc. Natl. Acad. Sci. USA 101, 17867-17872 (2004). (Pubitemid 40051978)
31. Direct Inhibition of delta-Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction (DELTA MI) Investigators, Bates, E. et al. Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation 117, 886-896 (2008).